The Role of Glycemic Control in the Management of Erectile Dysfunction among Patients with Type 2 Diabetes

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Erectile dysfunction (ED) has been a common complication among men with type 2 diabetes mellitus (T2DM), affecting up to 75% of this population. The interplay between poor glycemic control and the development of ED was multifaceted, involving vascular impairment, neuropathy, hormonal imbalances, and oxidative stress. Chronic hyperglycemia contributed to endothelial dysfunction, reduced nitric oxide availability, and nerve damage, all of which negatively impact erectile function. Glycemic management, therefore, played a crucial role in both preventing and treating ED in diabetic patients. This review investigated the pathophysiological mechanisms linking hyperglycemia to ED, evaluates the impact of glycemic control on erectile function, and explored therapeutic strategies that integrate glycemic management with ED treatment. Comprehensively, analysis of recent clinical studies and reviews addressing the relationship between glycemic control and ED outcomes in diabetic patients were the methods utilized in assembling this paper. Findings suggested that tight glycemic control (HbA1c < 7.0%) not only reduces the incidence of ED but also enhanced the effectiveness of pharmacological treatments like phosphodiesterase type 5 (PDE5) inhibitors. Additionally, lifestyle modifications and testosterone replacement therapy (TRT) are beneficial in managing both T2DM and ED, particularly when combined with improved glycemic control. Future research should focus on personalized treatment protocols and emerging therapies to optimize outcomes for this population.

Keywords: Glycemic control, Erectile dysfunction, Type 2 diabetes mellitus (T2DM), Endothelial dysfunction, Phosphodiesterase type 5 (PDE5) inhibitors.

CITE AS: Kato Jumba K. (2024). The Role of Glycemic Control in the Management of Erectile Dysfunction among Patients with Type 2 Diabetes. IDOSR JOURNAL OF BIOLOGY, CHEMISTRY AND PHARMACY 9(2):20-25. https://doi.org/10.59298/IDOSR/JBCP/24/92.202500